Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Oxbow Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,247 shares of the biopharmaceutical company’s stock, valued at approximately $2,950,000.

Several other institutional investors also recently added to or reduced their stakes in REGN. PGGM Investments raised its position in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares during the period. Osaic Holdings Inc. grew its stake in Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares in the last quarter. Generate Investment Management Ltd bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $6,300,000. Hudson Value Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $398,000. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after acquiring an additional 73,176 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $1.96 during mid-day trading on Friday, hitting $753.55. 721,001 shares of the company traded hands, compared to its average volume of 734,749. The stock has a fifty day moving average price of $755.38 and a 200-day moving average price of $643.06. The stock has a market cap of $79.20 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company posted $12.46 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on REGN shares. Citigroup boosted their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $794.70.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.